BB Biotech (BION)

Last close As at 18/05/2024

CHF41.75

−0.05 (−0.12%)

Market capitalisation

CHF2,313m

BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–35 stock portfolio.

Latest Insights

View More

Investment Companies | Update

BB Biotech — A cutting-edge sector and a high dividend

Investment Companies | Update

BB Biotech — Picking growth at good value

Investment Companies | edison tv

BB Biotech – executive interview

Investment Companies | Review

BB Biotech — Great valuation potential

Healthcare business concept, Medical examination and growth graph data of business on tablet with doctor's health report clipboard on background.

Equity Analyst

Joanne Collins

Joanne Collins

Analyst, Investment Trusts

Key Management

  • Claude Mikkelsen

    Director of IR

  • Daniel Koller

    Head of investment management

  • Dr Silvia Siegfried-Schanz

    Director of IR

  • Erich Hunziker

    Chairman

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (2.2) (14.9) (4.5)
Relative (8.4) (19.4) (7.9)
52 week high/low CHF49.4/CHF35.6

Overview

BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. BION is the largest biotech investor among its investment company peers. It invests in high-quality biotech assets that target substantial market opportunities. BION’s managers are optimistic about the outlook for the sector. They believe sentiment towards the sector should improve as interest rates peak and begin to decline. Meanwhile, they expect to see ongoing fundamental progress by portfolio holdings, with several due to reach key regulatory, clinical or commercial milestones over coming months. In addition, historically low valuations have created opportunities to add or top up exposure to interesting companies at attractive prices. BION differentiates itself from its peers by its highly competitive dividend policy – it pays a dividend equivalent to 5% of the average share price over December each year.

Research

Review

Investment Companies

BB Biotech — Great valuation potential

edison tv

Investment Companies

BB Biotech – executive interview

edison tv

Investment Companies

BB Biotech – fund manager interview

Review

Investment Companies

BB Biotech — RNA focus provides a possible COVID-19 solution

Review

Investment Companies

BB Biotech — Concentrated portfolio offering true differentiation

Review

Investment Companies

BB Biotech — Strong focus on emerging clinical areas

Review

Investment Companies

BB Biotech — High-conviction specialist with impressive record

Review

Investment Companies

BB Biotech — Update 27 February 2017

Thematics

thematic

Investment Companies

UK stock market – Scope for further upside in UK large-cap stocks

thematic

Investment Companies

Listed private equity – Performing a balancing act

thematic

Investment Companies

European equities

thematic

Investment Companies

Listed Private Equity

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free